about
TSPO imaging in parkinsonian disordersDegeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson's DiseaseOxidative stress and Parkinson's diseaseCellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's diseaseCB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease.Isobavachalcone Attenuates MPTP-Induced Parkinson's Disease in Mice by Inhibition of Microglial Activation through NF-κB PathwayThe 1-Tosylpentan-3-one Protects against 6-Hydroxydopamine-Induced NeurotoxicityAnti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson's disease models are mediated by GPR109A-dependent mechanisms.Comorbidities in Neurology: Is adenosine the common link?Alteration in Nuclear Factor-KappaB Pathway and Functionality of Estrogen via Receptors Promote Neuroinflammation in Frontal Cortex after 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine TreatmentAlpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T MutantPentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson's Disease.GLP-2 Attenuates LPS-Induced Inflammation in BV-2 Cells by Inhibiting ERK1/2, JNK1/2 and NF-κB Signaling Pathways.Immortalized Parkinson's disease lymphocytes have enhanced mitochondrial respiratory activityInflammation and adaptive immunity in Parkinson's disease.Microglial dynamics and role in the healthy and diseased brain: a paradigm of functional plasticitySenescence and cancer: An evolving inflammatory paradox.Aging and computational systems biology.l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?Commentary: IL-4 and IL-13 receptors and signalingA Novel Immunosuppressor, (5R)-5-Hydroxytriptolide, Alleviates Movement Disorder and Neuroinflammation in a 6-OHDA Hemiparkinsonian Rat Model.Ceruloplasmin potentiates nitric oxide synthase activity and cytokine secretion in activated microglia.Neuroglia: Functional Paralysis and Reactivity in Alzheimer's Disease and Other Neurodegenerative Pathologies.Neuroimmunomodulatory properties of DPSCs in an in vitro model of Parkinson's disease.Melatonin rescues zebrafish embryos from the parkinsonian phenotype restoring the parkin/PINK1/DJ-1/MUL1 network.Evaluation of exercise-induced modulation of glial activation and dopaminergic damage in a rat model of Parkinson's disease using [11C]PBR28 and [18F]FDOPA PET.Mutant A53T α-Synuclein Improves Rotarod Performance Before Motor Deficits and Affects Metabolic Pathways.Single-Cell RNA-Seq of Mouse Dopaminergic Neurons Informs Candidate Gene Selection for Sporadic Parkinson Disease.Regional microglia are transcriptionally distinct but similarly exacerbate neurodegeneration in a culture model of Parkinson's disease.Time to get Personal: A Framework for Personalized Targeting of Oxidative Stress in Neurotoxicity and Neurodegenerative Disease
P2860
Q26747214-2447ECE3-D61B-463A-BAD5-EC4E2A92DB06Q26750370-C1BA3446-E5C4-48C2-B59D-EB21BE8BD07AQ26798897-C058A7C7-3A43-49AD-9BFB-55FDB9893D2AQ26849232-CB280106-5C97-4393-AF62-5CFE730C8774Q27324500-9A5671C2-D7FA-4D51-9C0B-5945D7768E4AQ28468427-8746B55C-C3B8-4495-BA72-3D790BEB518EQ32176923-8656868B-C165-4BE3-92CF-99BC9638A69BQ35025103-0C328512-1CA0-4A4E-B1D0-B2E88D29C895Q35956389-72CDF23B-FC64-4B8B-8A6E-4B9C7E825DD5Q36056363-0DA4F42F-F004-4BAA-A89C-B9F17E90FBD2Q36131340-643567E1-A656-473D-B7DD-6C8380BBCAB5Q36154563-A817B64E-4CA4-4A68-8DEF-6A07A9F4620AQ36667043-12531092-49E7-48C0-A34C-F863679A26FFQ37425957-112EC122-8BF3-4520-9203-8560AF43C7BFQ37982378-A8F27FDF-2123-482C-B2A0-2426D9EAAEF5Q38203788-79FE390E-F92B-4AEF-BB04-25CD8A5285ECQ38603571-8ADC30FA-0330-433D-B9A0-E693ED62CF94Q38716151-2522C9AF-ED2D-4929-9F79-6CED40B4B65AQ38951947-B6E6617B-0023-47B4-9603-5F497885812DQ41818218-7620BEB1-43BA-4363-B26E-B02537B3F4DFQ42048890-1222C34F-3E8E-413B-8AD1-7888A2C4BA2CQ42914107-525A5F5D-1B15-450E-B6AA-E2740CA7E83BQ45303020-F51A959A-F98F-4A5F-BE2F-DF889A615796Q46339332-E88A0395-73C8-4BA3-800C-098BB384504DQ46967068-02E2570C-C960-4755-A043-F23482B50ACBQ47260664-6DD10895-FB41-4157-8076-B80447C8497BQ48565252-80C90773-559F-49F1-B426-61A2DEF21630Q52677022-145A2020-997B-4EF2-92B8-3CD6FC16B181Q54960390-47C08053-EF3A-47EE-8911-FE9649B69302Q57148215-B1A96A96-1668-4D00-A7B7-B217280E1E01
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Innate inflammation in Parkinson's disease.
@en
type
label
Innate inflammation in Parkinson's disease.
@en
prefLabel
Innate inflammation in Parkinson's disease.
@en
P2860
P1476
Innate inflammation in Parkinson's disease.
@en
P2093
V Hugh Perry
P2860
P304
P356
10.1101/CSHPERSPECT.A009373
P577
2012-09-01T00:00:00Z